« Return to News | CROs/Service Providers

Molecular Imaging partners with Dana-Faber Cancer Institute

Thursday, December 15, 2011 08:15 AM

Molecular Imaging has entered into a licensing agreement with Dana-Farber Cancer Institute to access a substantial number of luciferase-enabled cancer cell lines developed at Dana-Farber. Access to these lines expands Molecular Imaging’s ability to apply bioluminescent imaging technology to a broad array of cancer disease models, including expanded capability in various leukemias, multiple myeloma, triple-negative breast cancer, glioma and melanoma.  

“This licensing relationship gives Molecular Imaging access to over 100 additional luc-enabled cell lines, providing the ability to use imaging in a much broader array of cancer disease models, with greater confidence.  Access to the knowledge and skills of Drs Kung and Armstrong only makes the opportunity to advance the science of imaging more compelling.  We look forward to collaborating with Andrew and Scott in making these cell lines available as part of our services to pharmaceutical and biotechnology companies to enhance R&D decision-making,” said W. R. Leopold, PhD, VP, research and development, at Molecular.

Molecular Imaging expects to nearly triple its validated luc-reporter cell line library by end of first quarter 2012. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.